3 completed, 2 recruiting, 1 terminated. 3 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow MERRF Syndrome: new trials by email Literature Review of MERRF Syndrome trials Research Report on MERRF Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD). Promoting Resilience in Stress Management (PRISM), Clinical-focused narrative (CFN) - Mitochondrial Diseases, Mitochondrial Myopathies | Phase 1 / Phase 2 | Completed | Children's Hospital of Philadelphia | 16 | 2023-09-22 | 2024-11-29 |
| OMT-28 in Patients With Primary Mitochondrial Disease (PMD) (PMD-OPTION) OMT-28 - Primary Mitochondrial Disease | Phase 2 | Completed | Omeicos Therapeutics GmbH | 28 | 2023-05-22 | 2026-01-22 |
| A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease Vatiquinone - Inherited Mitochondrial Disease | Phase 3 | Completed | PTC Therapeutics | 101 | 2022-06-22 | 2025-12-22 |
| A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy Vatiquinone, Placebo - Mitochondrial Diseases, Drug Resistant Epilepsy | Phase 2 / Phase 3 | Terminated | PTC Therapeutics | 68 | 2020-09-28 | 2026-03-31 |
| North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) Mitochondrial Disorders, Mitochondrial Genetic Disorders | Recruiting | Columbia University | 1000 | 2011-01-31 | 2026-02-04 | |
| Global Registry and Natural History Study for Mitochondrial Disorders Mitochondrial Diseases, Kearns-Sayre Syndrome | Recruiting | LMU Klinikum | 6000 | 2009-02-01 | 2026-08-07 |
MELAS Syndrome (6) · Leigh Disease (4) · Mitochondrial Diseases (4) · Mitochondrial Myopathies (3) · Acidosis, Lactic (2) · Barth Syndrome (2) · Deafness (2) · Diffuse Cerebral Sclerosis of Schilder (2) · Drug Resistant Epilepsy (2) · Kearns-Sayre Syndrome (2) · Mitochondrial Encephalomyopathies (2) · Mitochondrial encephalopathy (2) · Neuropathy ataxia and retinitis pigmentosa (2) · Ophthalmoplegia, Chronic Progressive External (2)
Brain Diseases, Metabolic (6) · Brain Diseases, Metabolic, Inborn (6) · Cardiovascular Diseases (6) · Central Nervous System Diseases (6) · Cerebral Small Vessel Diseases (6) · Cerebrovascular Disorders (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Epilepsies, Myoclonic (6) · Epilepsy (6) · Epilepsy, Generalized (6) · Epileptic Syndromes (6) · Genetic Diseases, Inborn (6) · Metabolic Diseases (6) · Metabolism, Inborn Errors (6) · Musculoskeletal Diseases (6)
PTC Therapeutics (2) · Children's Hospital of Philadelphia (1) · Columbia University (1) · LMU Klinikum (1) · Omeicos Therapeutics GmbH (1)
Italy (4) · United States (4) · Canada (2) · France (2) · Germany (2) · Japan (2) · Poland (2) · Spain (2) · United Kingdom (2) · Austria (1) · Netherlands (1) · Sweden (1)
Vinay Penematsa, MD (2) · Elizabeth M McCormick, MS (1) · Michelangelo Mancuso, Prof. Dr. (1) · Michio Hirano, MD (1) · Robert Fischer, MD (1) · Thomas Klopstock, Prof. Dr. (1)
U54NS078059 (2)